Abbvie
Project Manager, Portfolio Program Management Operations, Abbvie Gpr and D
Abbvie Jun 2013 - Dec 2013
In Vivo Pharmacology Leader, Immunology-Dermatology
Abbvie/Abbott Aug 2010 - May 2013
Group Leader, Neuroscience and Pain Drug Discovery
Abbott Jan 2007 - Aug 2010
Senior Scientist Ii
Abbott May 2003 - Dec 2006
Senior Research Pharmacologist
Education:
University of Iowa 1997 - 2006
Doctorates, Doctor of Philosophy, Philosophy, Pharmacology
University of Mumbai 1992 - 1996
Bachelors, Bachelor of Science, Pharmacy
Skills:
Drug Discovery Pharmacology In Vivo Pharmaceutical Industry Neuroscience Drug Development Clinical Development Animal Models Immunology Biomarkers Translational Medicine Assay Development Cro In Vitro Toxicology Ion Channels Pharmacokinetics Gpcrs Biomarker Discovery Pain Management Inflammation Pain
Vincent Louis Giranda - Gurnee IL, US Alexander R. Shoemaker - Green Oaks IL, US Kaitlin E. Browman - Deerfield IL, US Shailen K. Joshi - Grayslake IL, US Thomas D. Penning - Elmhurst IL, US
Assignee:
ABBOTT LABORATORIES - Abbott Park IL
International Classification:
A61K 31/4184 A61K 33/24 A61P 25/02 A61K 31/437
US Classification:
424649, 514394, 514283
Abstract:
The present invention relates to the method of treating chemotherapy-induced neuropathy in a subject in need thereof with the use of a poly(ADP-ribose)polymerase (PARP) inhibitor.
Connie R. Faltynek - Highland Park IL, US Arthur R. Gomtsyan - Vernon Hills IL, US Marie P. Honore - Evanston IL, US Michael F. Jarvis - Vernon Hills IL, US Shailen K. Joshi - Grayslake IL, US Michael E. Kort - Lake Bluff IL, US Philip R. Kym - Libertyville IL, US Torben R. Neelands - Deerfield IL, US Regina M. Reilly - Libertyville IL, US Carol S. Surowy - Sturtevant WI, US
Disclosed herein are methods for increasing analgesic potency of TRPV1 antagonists, said methods comprise of repeated administration of the TRPV1 antagonists in a subject. Methods for treating or preventing pain by repeated administration of a TRPV1 antagonist are also discussed.
The present invention relates to the method of treating chemotherapy-induced neuropathy in a subject in need thereof with the use of a poly(ADP-ribose)polymerase (PARP) inhibitor.